Patent ID: 6358941
Filing Date: 2002-03-19
Classification: A61K,Y10S

Abstract:
A method of treatment of an arthritic disorder, or a rheumatoid disease associated therewith wherein the rheumatoid disease is selected from the group consisting of systemic lupus erythematosis, psoriatic arthritis and chronic anemia, comprising administering to a patient an effective amount of galantamine, a galantamine compound or a salt thereof, wherein said galantamine, galantamine derivative, or salt thereof has the general formula I: wherein the broken line represents an optionally present double bond between carbon 3 and 4, each R1 is independently selected from hydrogen, hydroxyl, straight or branched chain alkyl, hydroxyalkyl, carboxyalkyl amino, alkyiamino, acyl, lower alkanoyl, cyano, sulfhydryl, C1-6alkoxy, aryloxy, arylthio, R3-substituted aryloxy, R3-substituted arylthio, aralkoxy, an optionally R-3 substituted aliphatic or aryl carbarnyl group, aralkylthio, R3-substituted aralkoxy, R3 substituted aralkylthio, aryloxymethyl, R3-substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, R3-substituted benzoyloxy, aryloxycarbonyl, and R3-substituted aryloxycarbonyl, R2 is selected from hydrogen, straight or branched chain C1-6 alkyl, alkenyl or alkaryl group optionally substituted by a halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroaryl-alkyl, aryl, arylalkyl, cyano, amyl, aroyl, cycloalkylmethyl, allyl, phenyl, R3-substituted phenyl, alkylphenyl, R3-substituted alkylphenyl, heterocyclyl selected from &agr;- or &bgr;-furyl, &agr;- or &bgr;-thienyl or thenyl, pyridyl, pyrazinyl, and pyrimidly, alkyl-heterocyclyl or Râ€²-substituted heterocyclyl, where Râ€² is alkyl or alkoxy,each R3 is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, hydroxyalkyl, aryl, aralkyl, alkoxy, mercaptoalkyl, aryloxy, thiaryloxy, alkaryloxy, mercapto-alkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo, iodo, and trifluoromethyl, each R4 is independently selected from hydrogen, halo, trifluoromethyl or C1-4-alkyl, each R5 is independently selected from hydrogen or hydroxymethyl, R6 is hydrogen or C1-6-alkyl, or when R1 is hydroxyl, R6 may be a moiety of formula I wherein R6 is hydrogen and R1 is a linking bond; or R1 and R6 may jointly form semicarbazone, X is oxygen or NR3, Y is nitrogen or phosphorus, and pharmaceutically acceptable acid addition salts thereof.